Online inquiry

IVTScrip™ mRNA-Anti-HA, CT-P23(Cap 0, 2-Thio-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ6457MR)

This product GTTS-WQ6457MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets HA gene. The antibody can be applied in Influenza A infection research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq YP_308669.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3654620
UniProt ID Q9Q0U6
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-HA, CT-P23(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) (GTTS-WQ6457MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ13988MR IVTScrip™ mRNA-Anti-GP, REGN-3470-3471-3479(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA REGN-3470-3471-3479
GTTS-WQ4468MR IVTScrip™ mRNA-Anti-SLAMF7, BMS-901608(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA BMS-901608
GTTS-WQ4779MR IVTScrip™ mRNA-Anti-TNFSF13B, BR3-Fc(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA BR3-Fc
GTTS-WQ14057MR IVTScrip™ mRNA-Anti-C5, REGN-3918(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA REGN-3918
GTTS-WQ11803MR IVTScrip™ mRNA-Anti-PDCD1, MK-3475(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA MK-3475
GTTS-WQ1497MR IVTScrip™ mRNA-Anti-CD79B, ACD79B-VCMMAE(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA ACD79B-VCMMAE
GTTS-WQ6058MR IVTScrip™ mRNA-Anti-IL6, CNTO 136(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA CNTO 136
GTTS-WQ8771MR IVTScrip™ mRNA-Anti-PCSK9, IBI-306(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA IBI-306
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW